This work aimed to determine whether baseline serum 25-hydroxyvitamin D (25-OHD) concentrations show any link with quality of life (QoL) and pain perception in patients experiencing chronic pain who had been on long-term prescription opioids ahead of planned opioid detoxification. A prospective evaluation was performed on 45 patients with chronic pain maintained on extended prescription opioid therapy and scheduled for elective detoxification. Serum 25-OHD levels were quantified at baseline, before the start of detoxification, and patients were classified as vitamin D deficient (< 75 nmol/L) or sufficient (≥ 75 nmol/L). Quality of life was measured using the SF-36v2TM questionnaire, and pain intensity was recorded using a Visual Analog Scale (VAS) before any intervention. Before detoxification, the mean pain scores for patients with adequate baseline 25-OHD levels versus those with deficient levels were 6.06 ± 2.32 and 6.86 ± 2.10, respectively (corresponding normalized scores: 1.22 ± 0.571 versus 0.950 ± 0.632; p = 0.164). Review of the SF-36v2™ questionnaire data indicated only minor differences between the groups (35.00 ± 14.198 versus 34.97 ± 13.52), suggesting no meaningful association between vitamin D status and QoL (p = 0.913). Analysis of pretreatment 25-OHD concentrations with quality-of-life scores and pain ratings failed to reveal a statistically significant correlation. This suggests that variations in baseline vitamin D levels are unlikely to exert a substantial effect on either QoL or perceived pain intensity in this patient group. Future research is needed to establish clearer guidance on the assessment and management of vitamin D status among individuals with chronic pain who require prolonged prescription opioid treatment.
